Medigene AG (MDGEF)
USD 2.59
(0.0%)
USD 2.59
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 10.65 Million EUR | -27.31% |
| 2022 | 14.65 Million EUR | -0.02% |
| 2021 | 14.65 Million EUR | -32.15% |
| 2020 | 21.59 Million EUR | -21.16% |
| 2019 | 27.39 Million EUR | 26.43% |
| 2018 | 21.66 Million EUR | -15.93% |
| 2017 | 25.77 Million EUR | -22.2% |
| 2016 | 33.12 Million EUR | 40.69% |
| 2015 | 23.54 Million EUR | 203.58% |
| 2014 | 7.75 Million EUR | 52.3% |
| 2013 | 5.09 Million EUR | 17.95% |
| 2012 | 4.31 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 9.15 Million EUR | 0.0% |
| 2023 Q4 | 10.65 Million EUR | 0.0% |
| 2023 Q1 | - EUR | -100.0% |
| 2023 Q2 | 11.98 Million EUR | 0.0% |
| 2023 Q3 | 10.65 Million EUR | -11.17% |
| 2023 FY | 10.65 Million EUR | -27.31% |
| 2022 Q2 | 17.35 Million EUR | 0.0% |
| 2022 FY | 14.65 Million EUR | -0.02% |
| 2022 Q1 | - EUR | -100.0% |
| 2022 Q4 | 14.65 Million EUR | 0.0% |
| 2022 Q3 | 14.65 Million EUR | -15.59% |
| 2021 Q4 | 14.65 Million EUR | 0.0% |
| 2021 Q3 | 14.65 Million EUR | -15.87% |
| 2021 FY | 14.65 Million EUR | -32.15% |
| 2021 Q2 | 17.41 Million EUR | 0.0% |
| 2021 Q1 | - EUR | -100.0% |
| 2020 FY | 21.59 Million EUR | -21.16% |
| 2020 Q2 | 23.76 Million EUR | 0.0% |
| 2020 Q3 | 21.59 Million EUR | -9.1% |
| 2020 Q4 | 21.59 Million EUR | -0.0% |
| 2020 Q1 | - EUR | -100.0% |
| 2019 Q3 | 31.61 Million EUR | 4.06% |
| 2019 Q1 | 26.06 Million EUR | 20.3% |
| 2019 Q2 | 30.37 Million EUR | 16.56% |
| 2019 FY | 27.39 Million EUR | 26.43% |
| 2019 Q4 | 27.39 Million EUR | -13.35% |
| 2018 Q2 | 29.24 Million EUR | 16.75% |
| 2018 FY | 21.66 Million EUR | -15.93% |
| 2018 Q4 | 21.66 Million EUR | -25.41% |
| 2018 Q3 | 29.04 Million EUR | -0.69% |
| 2018 Q1 | 25.05 Million EUR | 35.86% |
| 2017 Q2 | 29.46 Million EUR | -4.53% |
| 2017 Q1 | 30.86 Million EUR | -6.82% |
| 2017 FY | 25.77 Million EUR | -22.2% |
| 2017 Q4 | 18.43 Million EUR | -28.57% |
| 2017 Q3 | 25.81 Million EUR | -12.39% |
| 2016 FY | 33.12 Million EUR | 40.69% |
| 2016 Q2 | 18.02 Million EUR | -18.0% |
| 2016 Q4 | 33.12 Million EUR | 0.01% |
| 2016 Q1 | 21.98 Million EUR | -6.63% |
| 2016 Q3 | 33.12 Million EUR | 83.75% |
| 2015 Q4 | 23.54 Million EUR | -1.74% |
| 2015 Q1 | 8.75 Million EUR | 12.91% |
| 2015 Q3 | 23.96 Million EUR | 12.16% |
| 2015 Q2 | 21.36 Million EUR | 143.97% |
| 2015 FY | 23.54 Million EUR | 203.58% |
| 2014 Q2 | 4.59 Million EUR | -14.42% |
| 2014 FY | 7.75 Million EUR | 52.3% |
| 2014 Q4 | 7.75 Million EUR | 86.02% |
| 2014 Q3 | 4.16 Million EUR | -9.25% |
| 2014 Q1 | 5.36 Million EUR | 5.42% |
| 2013 Q1 | 4.44 Million EUR | 3.01% |
| 2013 Q3 | 3.51 Million EUR | -7.4% |
| 2013 Q2 | 3.79 Million EUR | -14.57% |
| 2013 Q4 | 5.09 Million EUR | 44.74% |
| 2013 FY | 5.09 Million EUR | 17.95% |
| 2012 Q4 | 4.31 Million EUR | 23.98% |
| 2012 FY | 4.31 Million EUR | 0.0% |
| 2012 Q3 | 3.48 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 80.021% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -11.146% |
| SQZ Biotechnologies Company | 50.03 Million USD | 78.717% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 85.304% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 81.953% |
| Mesoblast Limited | 188.44 Million USD | 94.348% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -176.521% |
| Genus plc | 485 Million USD | 97.804% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -82.281% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -323.236% |
| Marizyme, Inc. | 26.67 Million USD | 60.076% |
| ContraFect Corporation | 32.53 Million USD | 67.262% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -180.263% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -437.524% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -178.239% |
| Intellipharmaceutics International Inc. | 12 Million USD | 11.315% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 9.579% |
| MultiCell Technologies, Inc. | 1617.67 USD | -658254.3% |
| Accustem Sciences Inc. | 1.07 Million USD | -886.806% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 86.243% |
| EV Biologics, Inc. | 2.11 Million USD | -403.53% |
| Q BioMed Inc. | 8.13 Million USD | -30.949% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 87.159% |
| Neon Bloom, Inc. | 1.22 Million USD | -768.528% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -106.955% |
| Biomind Labs Inc. | 1.49 Million USD | -610.658% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 244.07 Million USD | 95.637% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 42.13% |
| Skye Bioscience, Inc. | 14.07 Million USD | 24.319% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -429.816% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -7394.986% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -12.509% |
| IMV Inc. | 37.93 Million USD | 71.924% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -5195.451% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -85.352% |
| GB Sciences, Inc. | 5.41 Million USD | -96.583% |
| Alpha Cognition Inc. | 7.16 Million USD | -48.644% |
| HST Global, Inc. | 593.59 Thousand USD | -1694.159% |
| CSL Limited | 18.62 Billion USD | 99.943% |
| Halberd Corporation | 728.71 Thousand USD | -1361.469% |
| Enzolytics Inc. | 365.26 Million USD | 97.084% |
| Resverlogix Corp. | 67.39 Million USD | 84.198% |
| Affymax, Inc. | 8.87 Million USD | -20.054% |
| SYBLEU INC | 681.41 Thousand USD | -1462.929% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -1169.774% |
| argenx SE | 444.95 Million USD | 97.606% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 85.785% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -521.354% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 10.528% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -190.574% |
| AVAX Technologies, Inc. | 3.99 Million USD | -166.667% |
| Zenith Capital Corp. | 27.56 Thousand USD | -38530.346% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.197% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -4362.527% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -185.194% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -1464.258% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 91.029% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -17.781% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -15812.385% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -642.75% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 78.812% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -292.751% |
| BioStem Technologies, Inc. | 15.9 Million USD | 33.039% |
| ONE Bio Corp. | 27.49 Million USD | 61.267% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -2191.806% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -38721.857% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -745.78% |
| Agentix Corp. | 2.51 Million USD | -324.209% |
| LadRx Corporation | 2.2 Million USD | -383.975% |
| Cell Source, Inc. | 15.8 Million USD | 32.624% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -23727.636% |
| Regen BioPharma, Inc. | 5.45 Million USD | -95.14% |
| Regen BioPharma, Inc. | 5.45 Million USD | -95.14% |
| NovAccess Global Inc. | 7.86 Million USD | -35.484% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 56.963% |
| Itoco Inc. | 1.65 Million USD | -544.224% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -419.116% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -76.062% |
| Kadimastem Ltd | 3.5 Million USD | -203.863% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -2426.283% |
| CytoDyn Inc. | 127.89 Million USD | 91.673% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -25379.078% |
| Mobile Lads Corp. | 1.31 Million USD | -710.813% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -579.913% |
| Qrons Inc. | 1.48 Million USD | -615.383% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 3.579% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -1216.775% |
| Rebus Holdings, Inc. | 5.24 Million USD | -103.167% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -74.536% |
| International Stem Cell Corporation | 5.27 Million USD | -101.819% |
| Bioxytran, Inc. | 3.24 Million USD | -227.743% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -1601.797% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -130.663% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 74.022% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 52.167% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -425.825% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -94.414% |
| Neutra Corp. | 973.52 Thousand USD | -993.958% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 63.295% |
| PureTech Health plc | 125.58 Million USD | 91.52% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -183.461% |
| IXICO plc | 1.9 Million USD | -460.44% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 48.122% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 89.693% |
| CSL Limited | 18.62 Billion USD | 99.943% |
| Cellectis S.A. | 249.36 Million USD | 95.729% |